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Europe must seek to improve its capacity to innovate through bringing the results of research to 
market when compared with its worldwide competitors such as China, the US, India and Brazil. 
Although part of the problem is lower spending of GDP on research and development a bigger issue 
is that the EU takes too long to transform research and innovation results into marketable products 
and historically has lacked the support mechanisms to bridge the EU ‘innovation valley of death’. 
However, with the European Commission’s proposal for a new European Strategic Framework for 
Research and Innovation, Horizon 2020, the EU has taken a decisive step towards improving its 
competitiveness. The proposed approach is the right one: to focus on developing demonstration 
biorefineries and to develop access to risk finance and partnerships for the development of 
sustainable bio-based products, processes and services. These moves will help Europeans to take 
advantage of the social, economic and environmental benefits of the bioeconomy. 
EuropaBio is therefore calling on the EU Member States to support Horizon 2020 by endorsing 
research and innovation in industrial biotechnology, and the bioeconomy including through the 
Public Private Partnerships (PPP) BRIDGE (Biobased and Renewable Industries for Growth and 
Development in Europe) and through safeguarding the budget allocated to both the Bioeconomy 
and to Industrial Biotechnology as a Key Enabling Technology. 
